Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 113 entries
View as:

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

Phase: N/A Priority: Normal
NCT ID: NCT03201445 Org: User:
Start: 07/11/17 End: 10/24/23 Due: 10/24/24

Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

Phase: N/A Priority: Normal
NCT ID: NCT01384422 Org: User:
Start: 06/30/11 End: 11/30/11 Due: 11/30/12

Long-term Follow-up of Participants Treated with Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

Phase: N/A Priority: Normal
NCT ID: NCT06652633 Org: User:
Start: 09/09/24 End: 07/31/39 Due: 07/31/40

GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01211249 Org: User:
Start: 10/31/10 End: 04/30/11 Due: 04/30/12

First-in-Human Single Ascending and Multiple Dose of GLPG0259

Phase: N/A Priority: Normal
NCT ID: NCT00905138 Org: User:
Start: 03/31/09 End: 06/30/09 Due: 06/30/10

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

Phase: N/A Priority: Normal
NCT ID: NCT03733444 Org: User:
Start: 11/05/18 End: 03/30/21 Due: 03/30/22

Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02162355 Org: User:
Start: 06/30/14 End: 09/30/14 Due: 09/30/15

A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02788721 Org: User:
Start: 04/14/16 End: 04/27/17 Due: 04/27/18

First-in-Human Single Ascending and Multiple Dose of GLPG0555

Phase: N/A Priority: Normal
NCT ID: NCT01023321 Org: User:
Start: 12/31/09 End: 05/31/10 Due: 05/31/11

A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT03117270 Org: User:
Start: 03/07/17 End: 07/02/18 Due: 07/02/19

A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03899909 Org: User:
Start: 03/29/19 End: 06/03/19 Due: 06/03/20

First-in-Human Single Ascending Subcutaneous (s.c.) Dose and Single Oral Dose of GLPG0187

Phase: N/A Priority: Normal
NCT ID: NCT00928343 Org: User:
Start: 06/30/09 End: 12/31/09 Due: 12/31/10

Oral Bioavailability of Two Solid Formulations of GLPG0634

Phase: N/A Priority: Normal
NCT ID: NCT01915667 Org: User:
Start: 07/31/13 End: 09/30/13 Due: 09/30/14

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667

Phase: N/A Priority: Normal
NCT ID: NCT05335447 Org: User:
Start: 04/19/22 End: 06/03/22 Due: 06/03/23

Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.

Phase: N/A Priority: Normal
NCT ID: NCT03589313 Org: User:
Start: 02/12/18 End: 03/26/18 Due: 03/26/19

Oral Bioavailability of GLPG0555 in Different Solid Formulations

Phase: N/A Priority: Normal
NCT ID: NCT01278095 Org: User:
Start: 01/31/11 End: 03/31/11 Due: 03/31/12

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT04577794 Org: User:
Start: 10/05/20 End: 05/31/21 Due: 05/31/22

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

Phase: N/A Priority: Normal
NCT ID: NCT05479058 Org: User:
Start: 07/26/22 End: 10/09/23 Due: 10/09/24

Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food

Phase: N/A Priority: Normal
NCT ID: NCT02143856 Org: User:
Start: 05/31/14 End: 07/31/14 Due: 07/31/15

A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase: N/A Priority: Normal
NCT ID: NCT03725852 Org: User:
Start: 09/27/18 End: 08/14/20 Due: 08/14/21

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

Phase: N/A Priority: Normal
NCT ID: NCT04700280 Org: User:
Start: 01/28/21 End: 12/27/21 Due: 12/27/22

Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01665924 Org: User:
Start: 07/31/12 End: 10/31/12 Due: 10/31/13

Multiple Ascending Dose Study of GLPG0974 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01721980 Org: User:
Start: 10/31/12 End: 02/28/13 Due: 02/28/14

A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03045523 Org: User:
Start: 01/31/17 End: 08/11/17 Due: 08/11/18

Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03450720 Org: User:
Start: 06/28/17 End: 08/16/17 Due: 08/16/18